Comparison of Efficacy and Safety of Generic and Original-Patented Rivaroxaban in Prevention of Deep Vein Thrombosis After Total Hip and Total Knee Arthroplasties
Objective To evaluate the efficacy and safety of generic and original-patented rivaroxaban in the prevention of deep vein thrombosis(DVT)after total hip arthroplasty(THA)or total knee arthroplasty(TKA).Methods The patients planned to undergo the THA(96 cases)or TKA(63 cases)in the joint surgery department of the hospital from July 2016 to December 2022 were collected and divided into the original-patented group(91 cases)and the generic group(68 cases)according to different sources of rivaroxaban.The incidences of DVT and adverse drug reactions within three months after surgery in the two groups were compared.Results The incidence of DVT after surgery in the original-patented group and the generic group was 4.40%and 5.88%,the incidence of bleeding event was 1.10%and 0,the incidence of other adverse reactions(constipation,pain,lower limb swelling)was 3.30%and 7.35%respectively,with no significant difference between the groups(P>0.05).Conclusion The efficacy and safety of generic and original-patented rivaroxaban are comparable in the postoperative use of THA or TKA.
rivaroxabandeep vein thrombosistotal hip arthroplastytotal knee arthroplastyoriginal-patented druggeneric drugefficacysafety
万方数据
维普
